Last reviewed · How we verify
Fluticasone mono
At a glance
| Generic name | Fluticasone mono |
|---|---|
| Sponsor | MEDA Pharma GmbH & Co. KG |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Single Dose Pharmacokinetics of Intranasal Azelastine Delivered by a Fixed Combination With Fluticasone in Comparison to Azelastine Nasal Sprays (PHASE1)
- Single Dose Pharmacokinetics of Intranasal Fluticasone Delivered by a Fixed Combination With Azelastine (MP29 02) in Comparison to Two Different Fluticasone Nasal Sprays (PHASE1)
- Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study (PHASE2)
- Leukotriene Receptor Antagonists or Steroids in Pre-School Asthma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone mono CI brief — competitive landscape report
- Fluticasone mono updates RSS · CI watch RSS
- MEDA Pharma GmbH & Co. KG portfolio CI